Simplex Trading
NBIX icon

Simplex Trading’s Neurocrine Biosciences NBIX Stock Holding History

Simplex Trading’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.11M Sell
8,400
-4,200
-33% -$557K ﹤0.01% 2403
2025
Q4 		$1.79M Buy
12,600
+6,400
+103% +$927K ﹤0.01% 2082
2025
Q3 		$870K Buy
6,200
+5,600
+933% +$759K ﹤0.01% 3198
2025
Q2 		$75K Buy
600
+200
+50% +$22.9K ﹤0.01% 5511
2025
Q1 		$44K Sell
400
-1,200
-75% -$152K ﹤0.01% 5900
2024
Q4 		$218K Sell
1,600
-19,800
-93% -$2.45M ﹤0.01% 4424
2024
Q3 		$2.46M Sell
21,400
-46,100
-68% -$6.32M ﹤0.01% 2093
2024
Q2 		$9.29M Buy
67,500
+49,200
+269% +$6.75M 0.01% 1061
2024
Q1 		$2.52M Buy
18,300
+6,600
+56% +$901K ﹤0.01% 2172
2023
Q4 		$1.54M Buy
11,700
+1,000
+9% +$115K ﹤0.01% 2588
2023
Q3 		$1.2M Sell
10,700
-1,100
-9% -$116K ﹤0.01% 2499
2023
Q2 		$1.11M Buy
11,800
+11,500
+3,833% +$1.12M ﹤0.01% 2506
2023
Q1 		$30K Buy
+300
New +$31.2K ﹤0.01% 6493
2022
Q4 		– Sell
-1,600
Closed -$169K – 9966
2022
Q3 		$169K Buy
1,600
+200
+14% +$20.3K ﹤0.01% 4840
2022
Q2 		$136K Sell
1,400
-43,000
-97% -$3.97M ﹤0.01% 5136
2022
Q1 		$4.16M Buy
44,400
+26,500
+148% +$2.25M ﹤0.01% 1410
2021
Q4 		$1.52M Buy
17,900
+7,900
+79% +$727K ﹤0.01% 2336
2021
Q3 		$974K Buy
10,000
+100
+1% +$9.45K ﹤0.01% 3108
2021
Q2 		$963K Buy
9,900
+9,749
+6,456% +$934K ﹤0.01% 3175
2021
Q1 		$1.47M Buy
151
+22
+17% +$2.31K ﹤0.01% 1962
2020
Q4 		$1.24M Sell
129
-166
-56% -$16K ﹤0.01% 2287
2020
Q3 		$2.84M Buy
295
+185
+168% +$21.4K ﹤0.01% 1250
2020
Q2 		$1.34M Buy
110
+7
+7% +$774 ﹤0.01% 1862
2020
Q1 		$891K Buy
103
+72
+232% +$7.05K ﹤0.01% 1994
2019
Q4 		$333K Sell
31
-28
-47% -$2.93K ﹤0.01% 3171
2019
Q3 		$531K Sell
59
-57
-49% -$5.33K ﹤0.01% 2558
2019
Q2 		$979K Sell
116
-284
-71% -$23.3K ﹤0.01% 1922
2019
Q1 		$3.52M Buy
400
+282
+239% +$23.6K 0.01% 925
2018
Q4 		$842K Sell
118
-29
-20% -$2.78K ﹤0.01% 1771
2018
Q3 		$1.81M Buy
147
+71
+93% +$8.06K 0.01% 1328
2018
Q2 		$746K Buy
76
+16
+27% +$1.43K ﹤0.01% 2056
2018
Q1 		$15K Sell
60
-202
-77% -$17.1K ﹤0.01% 3635
2017
Q4 		$16K Buy
262
+134
+105% +$9.14K ﹤0.01% 3515
2017
Q3 		$4K Sell
128
-182
-59% -$9.6K ﹤0.01% 4580
2017
Q2 		$28K Buy
+310
New +$15K ﹤0.01% 2948
2017
Q1 		– Sell
-263
Closed -$122K – 6557
2016
Q4 		$122K Buy
263
+229
+674% +$10.4K 0.01% 1380
2016
Q3 		$2K Sell
34
-119
-78% -$5.93K ﹤0.01% 4993
2016
Q2 		$20K Buy
153
+94
+159% +$4.33K ﹤0.01% 2900
2016
Q1 		$12K Sell
59
-25
-30% -$992 ﹤0.01% 3314
2015
Q4 		$22K Sell
84
-59
-41% -$3K ﹤0.01% 2600
2015
Q3 		$122K Buy
143
+91
+175% +$4.4K 0.01% 1264
2015
Q2 		$13K Sell
52
-43
-45% -$1.82K ﹤0.01% 2847
2015
Q1 		$28K Sell
95
-96
-50% -$3.43K ﹤0.01% 2043
2014
Q4 		$21K Buy
+191
New +$3.62K ﹤0.01% 2013

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Simplex Trading's NBIX Position: Q1 2026 in Review

Simplex Trading increased its Neurocrine Biosciences (NBIX) stake by 22% in Q1 2026, buying an estimated $173K and bringing the position to 7,144 shares worth $941K. The position accounts for ﹤0.01% of the portfolio, ranked #2563.

Simplex Trading first reported a position in NBIX in Q4 2014 and has held it in 26 quarters since. The position peaked at $2.21M in Q1 2022. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Simplex Trading held 7,144 shares of Neurocrine Biosciences worth $941K as of Q1 2026.
  • Simplex Trading bought 1,307 Neurocrine Biosciences shares in Q1 2026, an estimated $173K.
  • Neurocrine Biosciences made up ﹤0.01% of Simplex Trading's portfolio in Q1 2026, its #2563 holding.
  • Simplex Trading first reported a position in Neurocrine Biosciences in Q4 2014 and has held it in 26 quarters since.
  • Simplex Trading's Neurocrine Biosciences position peaked at $2.21M in Q1 2022.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.